# Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal Cancer

> **NCT01919879** · PHASE2 · COMPLETED · sponsor: **UNICANCER** · enrollment: 75 (actual)

## Conditions studied

- Metastatic Colorectal Cancer

## Interventions

- **DRUG:** Cetuximab + Afatinib
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT01919879
- **Lead sponsor:** UNICANCER
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-10
- **Primary completion:** 2015-11
- **Final completion:** 2017-12
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2018-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01919879

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01919879, "Dual Targeting of EGFR With Cetuximab and Afatinib to Treat Refractory wtKRAS Metastatic Colorectal Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01919879. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*